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Abstract
Background: To analyze whether the determination of interleukin-6 levels in cerebrospinal fluid is useful as a biomarker for the severity
of bacterial meningitis. Methodology: Cerebrospinal fluid was obtained from 120 patients aged 0-15 years with meningitis. They were
classified as having bacterial meningitis (n = 85) or aseptic meningitis (n = 35) according to the cerebrospinal fluid white blood cell count,
microbiological  culture  and  molecular  methods.  Interleukin-6  levels  were  determined  by  enzyme-linked  immunosorbent  assay.
Results: No significant change in the mean interleukin-6 level on the basis of clinical signs was observed in patients with bacterial
meningitis. However, the cerebrospinal fluid total protein level was elevated in patients with alertness problems (3.41±2.26 g LG1). There
was a  significant  correlation (Pearson correlation p#0.05) between the cerebrospinal fluid glucose and total protein levels in patients
with bacterial meningitis. The mean cerebrospinal fluid interleukin-6 level (4,472.0±2,494.52  pg mLG1) in patients with bacterial
meningitis  whose  disease  outcome  was  fatal  was  significantly  higher  (p#0.05)  than  that  of   those   who   survived   the   disease
(2,983.28±2,612.13  pg mLG1). Conclusion:  Interleukin-6 is a potential biomarker for identifying bacterial meningitis patients with a high
risk of death who require intensive care.
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INTRODUCTION
Acute meningitis is responsible for rampant epidemics
each year in Africa in the “African meningitis belt1”. This
meningitis, primarily due to a meningococcus, remains a
public health problem. The establishment of new biomarkers
that allow the rapid and precise diagnosis of the disease while
also indicating its severity could improve care and reduce
mortality. Certain cytokines, such as interleukin-1 (IL-1),
interleukin-6  (IL-6),  interleukin-8  (IL-8),  tumor  necrosis 
factor-"  (TNF)  and  interferon  (IFN)  may  be  responsible  for
the severe inflammatory reaction associated with acute
meningitis. Thus, there may be a correlation between cytokine
concentrations in the cerebrospinal fluid (CSF) and morbidity
and  mortality2,3. The IL-6  is  a potential marker for the
diagnosis of  bacterial  meningitis4-7.  However,  inflammatory 
and anti-inflammatory cytokines are rarely measured for the
diagnosis or prognosis of meningitis8. A new CSF biomarker
that permits the differential diagnosis of meningitis and
prognostic evaluation of the disease could improve the
management of meningitis.
MATERIALS AND METHODS
This  is  a  prospective,  observational,  transversal  and
non-blinded study. Patient inclusion was conducted at the
Emergency Pediatric department of the National Hospital of
Niamey (HNN) from February-April, 2015. Clinical patient
information and microbiological culture results for patients
and their CSF glucose and CSF protein levels, determined by
the medical biology and biochemistry laboratories of the HNN
were collected from a data collection sheet. Aliquots of the
CSF supernatant obtained after centrifugation at 4000 rpm for
5 min was conserved at -20EC for IL-6 measurements and
bacterial identification by molecular biology at the Medical
and Health Research Center (CERMES).
Patients: This study included 120 patients with an average
age of 6.8±4.67 years of which 35 had aseptic meningitis
(leukocyte count >10   cells  mmG3 and no bacteria identified
by culture or molecular biology) and 85 had bacterial
meningitis identified by both microbiological culture and
molecular biology. The CSF sampling was performed at
admission before the start of antibiotic therapy with
ceftriaxone.
Measurement  of  CSF  biomarkers:  Glucose  (Cypress
Diagnostics,  Langdorp,  Belgium) and protein (Sprinreact, Sant
Esteve de Bas, Spain) contents of the CSF supernatant were
determined using an enzymatic, colorimetric method9-14.
An enzyme-linked immunosorbent assay (ELISA) method
using the Human IL-6 ELISA (EH2IL65) kit (Thermo Scientific,
USA)  was  used  to  measure  IL-6  in the CSF  supernatant.
Each  sample  was analyzed in duplicate and the absorbance
of  the  plates  measured  at 450 nm. The test has a sensitivity
<1 pg mLG1 and requires 50 µL of CSF supernatant. The results
are expressed in pg mLG1.
Bacteriological and molecular identification:  Bacteriological
identification involved culture on polyvitex chocolate agar or
blood agar using an API NH gallery for Neisseria  meningitidis
and Haemophilus influenzae  and the Alere BinaxNOW®
Streptococcus pneumoniae Antigen Card Kit (Alere Inc, USA)
for Streptococcus  pneumoniae.
A  conventional Multiplex Polymerase Chain Reaction
(PCR) was used to identify the three principle bacteria
responsible for bacterial meningitis: Neisseria  meningitidis
(crgA  gene), Streptococcus pneumoniae  (lytA  gene) and
Haemophilus influenzae  (bexA  gene). The genogroup of
Neisseria  meningitidis  was determined by multiplex  PCR that
first identifies the A, X and W genogroups and then the Y and
C genogroups for those that are negative in the first PCR15-17.
Statistics:  The  IBM  SPSS  Statistics  vs  20  software   was
used for statistical analysis. The Mann-Whitney U test was
performed to compare the groups. The Pearson correlation
was determined only for patients with results for the three
biomarkers. The p#0.05 was considered to be significant.
RESULTS
The distribution of the patients according to age and
gender and the mean values of the biomarkers depending on
the type of meningitis, are summarized in Table 1. The
principal bacterium identified in the cases of bacterial
meningitis  was  Neisseria  meningitides  (97.6%  of  cases):
77.6% were serogroup C, 11.8% serogroup W and 8.2%
undetermined.  Only  two  cases of  S.  pneumoniae   (2.4%)
were  identified.  There  was  a   significant    difference
(p<0.01) between  the  patients  with  bacterial  meningitis 
and  those with   aseptic   meningitis   for   the   CSF   IL-6  
concentration  (3,538.69±2,560.78  pg  mLG1  versus
332.51±470.69 pg mLG1), CSF glucose (1.31±1.59 mmol LG1
versus  3.01±2.09  mmol  LG1)  and  CSF  protein  levels
(3.09±2.79 g LG1 versus 1.70±1.79 g LG1). Biomarker values
associated with various clinical symptoms were determined:
(1)  Mean  CSF   protein   levels   were   significantly   higher   in
2
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Table 1: Population characteristics and biomarkers of patients included in the
study
Variable Aseptic meningitis Bacterial meningitis
Patientsa 35 (29.2%) 85 (70.8%)
Malea 17 (14.2%) 42 (35%)
Femalea 18 (15%) 43 (35.8%)
Age (years)b 5.43 (0-14) 8.43 (1-15)
CSF protein levelc 1.70±1.79 (n  = 18) 3.09±2.79 (n  = 65)
CSF glucose 3.01±2.09 (n  = 18) 1.31±1.59 (n  = 65)
level (mmol LG1)c
CSF IL-6 (pg mLG1) levelc 332.51±470.69 (n  = 35) 3,538.69±2560.78 (n = 85)
aResults are expressed as the number of patients (% of total number of patients),
bMean (minimum-maximum), cMean±SD (number of patients) and N: Number
of patients
bacterial meningitis patients with alertness problems
(3.41±2.26 g LG1, p#0.05) (Table 2) and (2) IL-6 levels were
higher in aseptic meningitis patients with  convulsions 
(1104.79±1534.16  pg  mLG1,  p#0.05) (Table 3). There was a
significant correlation (Pearson correlation, p<0.05) between
CSF glucose and protein levels, but not IL-6, in patients with
bacterial meningitis. The mean concentration of IL-6 at
admission was higher in patients for whom the disease
outcome    was    death    than   in   patients   who   survived
the   disease   (4,472.0±2,494.52    pg    mLG1   versus
2,983.28±2,612.13  pg mLG1, p#0.05) (Table 4).
Table 2: CSF IL-6, glucose and total protein values according to clinical signs of patients with bacterial meningitis
Variable CSF IL-6 (pg mLG1) CSF glucose (mmol LG1) CSF protein (g LG1)
Duration of the disease
#3 days 3,611.16±2554.29 (n  = 71) 1.26±1.44 (n  = 56) 2.78±2.15 (n  = 56)
>3 days 2,835.92±2350.75 (n  = 5) 0.07±0.04 (n  = 2) 11.21±9.59 (n = 2)
Fever
Yes 3,832.37±2611.03 (n = 44) 1.44±1.79 (n = 36) 3.38±3.26 (n = 36)
No 2,893.78±2308.59 (n = 27) 0.88±0.94 (n = 19) 3.00±2.29 (n = 19)
Neck stiffness
Yes 3,600.09±2579.48 (n = 57) 1.34±1.42 (n = 43) 3.220±3.11 (n = 43)
No 3,235.05±2580.09 (n = 24) 1.24±1.96 (n = 20) 2.670±2.13 (n = 20)
Convulsion
Yes 3,644.35±2699.52 (n = 35) 1.43±1.82 (n = 23) 3.47±2.49 (n = 23)
No 3,375.96±2488.92 (n = 40) 1.24±1.47 (n = 40) 2.80±3.01 (n = 40)
Alertness problems
Yes 3,541.42±2691.91 (n = 43) 1.24±1.40 (n = 35) 3.41±2.26* (n = 35)
No 3,435.93±2457.17 (n = 38) 1.40±1.84 (n = 28) 2.59±3.40 (n = 28)
Purpura
Yes 1.36±0.92 (n = 6) 2.31±2.12 (n = 6) 2,894.130±3273.18 (n = 6)
No 1.31±1.66 (n = 57) 3.12±2.90 (n = 57) 3,557.440±2449.44 (n = 73)
*p#0.05 and n: Number of patients 
Table 3: CSF IL-6, glucose and total protein values according to clinical signs of patients with aseptic meningitis
Variable  CSF IL-6 (pg mLG1) CSF glucose (mmol LG1) CSF protein (g LG1)
Duration of the disease
 #3 days 830.30±1308.69 (n = 27) 3.03±2.20 (n = 16) 1.59±1.79 (n = 16)
>3 days 17.37 (n = 1) 3.74 (n = 1) 0.24 (n = 1)
Fever
Yes 816.74±1257.22 (n = 17) 2.92±2.0 (n = 8) 1.17±1.49 (n = 8)
No 276.55±397.96 (n = 9) 3.30±1.92 (n = 6) 1.09±1.43 (n = 6)
Neck stiffness
Yes 1,344.25±1585.50 (n = 11) 2.29±1.76 (n = 5) 2.12±1.76 (n = 5)
No 435.9100±860.36 (n = 21) 3.39±2.26 (n = 12) 1.25±1.78 (n = 12)
Convulsion
Yes 1,104.79±1534.16* (n = 13) 2.49±2.74 (n = 8) 2.15±2.13 (n = 8)
No 504.1400±929.97 (n = 19) 3.58±1.38 (n = 9) 0.94±1.22 (n = 9)
Alertness problems
Yes 760.16±1279.82 (n = 14) 3.31±2.41 (n = 8) 1.00±1.10 (n = 8)
No 738.81±1219.90 (n = 18) 2.85±1.98 (n = 9) 1.96±2.16 (n = 9)
*p#0.05 and n: Number of patients     
Table 4: IL-6 values according to disease outcome of patients with bacterial meningitis
Variable CSF IL-6 (pg mLG1) CSF glucose (mmol LG1) CSF protein (g LG1)
Death 4,472.00±2494.52* (n = 21) 1.78±2.18 (n = 13) 4.47±4.82 (n = 13)
Survival 2,983.28±2612.13 (n = 48) 0.87±1.05 (n = 33) 3.19±2.0 (n = 33)
*p#0.05 and n: Number of patients
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DISCUSSION
The diagnosis of meningitis is primarily based on clinical
examination  and  the  analysis  of  CSF  cytology  and  CSF
glucose and protein levels18,19. Other biomarkers of CSF
including cytokines have been explored to increase the
number of available biological examinations that are
informative about the intensity of inflammation in the
subarachnoid space20. The central hypothesis of this study is
a possible link between the IL-6 concentration in the CSF and
both the clinical signs and outcome of the disease. The results
obtained show that the clinical signs of bacterial meningitis
are independent of the IL-6 concentration. In contrast, CSF
protein is higher in patients with than without alertness
problems. The increase in CSF protein levels following
inflammation in the subarachnoid space is one of the
physiopathological mechanisms that leads to nerve damage21.
This  nerve damage may be the direct consequence of
bacterial toxicity or due to the indirect effect of cytokine
secretion22,23. Alertness problems associated with bacterial
meningitis are a consequence of the increased protein
concentration in the CSF and convulsions in aseptic meningitis
a consequence of increased IL-6 in the CSF. Nevertheless, the
CSF IL-6 concentration is significantly higher in bacterial than
aseptic meningitis21,24,25.  A link between the increase in the
CSF IL-6 concentration in aseptic meningitis and nerve
damage has been reported21, this high IL-6 concentration does
not correlate with CSF glucose and protein levels. This study
did not find a relation between the CSF IL-6 concentration and
the duration of the illness and fever. In contrast, Hseih et al.4
found a significant increase in the CSF IL-6 concentration  if
the fever lasted longer than three days for both bacterial and
aseptic meningitis. In this study,  a link between high mean
CSF IL-6 concentration and a fatal outcome of the disease was
found. According  to Vazquez et al.26, an IL-6 concentration in
the CSF above 1000 pg dLG1 is associated with high morbidity
and  mortality  independent  of  the  clinical  signs  of  the
disease. In contrast, Misra et al.27 reported that the CSF IL-6
concentration does not correlate with the stage of the disease,
the severity, or the outcome in patients with tuberculin
meningitis. The IL-6, TNF" and IL-1$ are the principal
cytokines secreted first and act in synergy to stimulate a
cascade of inflammatory mediators28. This inflammatory
reaction is partially responsible for the physiopathological
consequences of bacterial meningitis such as the stimulation
of protein secretion (exudation), fever, leukocyte infiltration29
and neurological damage: Cerebral edema, cerebral
hypoperfusion, nerve damage23. The association between the
severity of inflammation in the  subarachnoid  space  and  the
mortality of meningitis has already been reported in
experimental  animal  models  of  bacterial  meningitis30,31.
There is also a correlation between the CSF IL-6 concentration
and neurological damage in cases of aseptic meningitis21,32.
Consequently,  the  use  of  dexamethasone  has  been
suggested  to  reduce  the  intensity  of  the  inflammatory
reaction in the subarachnoid space and the negative effects33.
This study coincided with a major meningitis epidemic34.
The  capacity  of  the  National  Hospital  of  Niamey  is  limited
and some patients were redirected to other centers such that
we do not know the outcome, also, in these conditions of
overload, CSF was not collected or not tested for some
patients. Medical follow-up of patients is not considered  in
this study. However, follow-up of these patients would be
valuable to evaluate the clinical value of assaying CSF IL-6.
CONCLUSION
The IL-6 is a potential biomarker for the identification of
bacterial meningitis patients with an elevated risk of dying
and who need intensive care. The IL-6 testing may identify
patients who do not require hospitalization and could be
treated at home, thereby freeing-up hospital beds for serious
cases, particularly during epidemics.
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